Literature DB >> 29449717

Reply to Brioude et al.

Jack Brzezinski1, Cheryl Shuman1, Sanaa Choufani1, Peter Ray1, Dimitri J Stavropoulos1, Raveen Basran1, Leslie Steele1, Nicole Parkinson1, Ronald Grant1, Paul Thorner1, Armando Lorenzo1, Rosanna Weksberg2.   

Abstract

Year:  2018        PMID： 29449717      PMCID： PMC5891490          DOI： 10.1038/s41431-017-0094-y

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN： 1018-4813            Impact factor:   4.246


× No keyword cloud information.
  11 in total

1.  Feasibility of partial nephrectomy for Wilms' tumor in children with Beckwith-Wiedemann syndrome who have been screened with abdominal ultrasonography.

Authors:  D Elizabeth McNeil; Jacob C Langer; Peter Choyke; Michael R DeBaun
Journal:  J Pediatr Surg       Date:  2002-01       Impact factor: 2.545

2.  Phenotype, cancer risk, and surveillance in Beckwith-Wiedemann syndrome depending on molecular genetic subgroups.

Authors:  Saskia M Maas; Fleur Vansenne; Daniel J M Kadouch; Abdulla Ibrahim; Jet Bliek; Saskia Hopman; Marcel M Mannens; Johannes H M Merks; Eamonn R Maher; Raoul C Hennekam
Journal:  Am J Med Genet A       Date:  2016-07-15       Impact factor: 2.802

3.  Tumor Screening in Beckwith-Wiedemann Syndrome: Parental Perspectives.

Authors:  Kelly A Duffy; Katheryn L Grand; Kristin Zelley; Jennifer M Kalish
Journal:  J Genet Couns       Date:  2017-12-04       Impact factor: 2.537

4.  Children with idiopathic hemihypertrophy and beckwith-wiedemann syndrome have different constitutional epigenotypes associated with wilms tumor.

Authors:  Emily L Niemitz; Andrew P Feinberg; Sheri A Brandenburg; Paul E Grundy; Michael R DeBaun
Journal:  Am J Hum Genet       Date:  2005-10-03       Impact factor: 11.025

5.  Paediatrics: Integrating genomics to dig deeper into Wilms tumour biology.

Authors:  William Mifsud; Kathy Pritchard-Jones
Journal:  Nat Rev Urol       Date:  2017-10-25       Impact factor: 14.432

6.  Wilms tumour in Beckwith-Wiedemann Syndrome and loss of methylation at imprinting centre 2: revisiting tumour surveillance guidelines.

Authors:  Jack Brzezinski; Cheryl Shuman; Sanaa Choufani; Peter Ray; Dmitiri J Stavropoulos; Raveen Basran; Leslie Steele; Nicole Parkinson; Ronald Grant; Paul Thorner; Armando Lorenzo; Rosanna Weksberg
Journal:  Eur J Hum Genet       Date:  2017-07-12       Impact factor: 4.246

7.  Characteristics and outcome of children with Beckwith-Wiedemann syndrome and Wilms' tumor: a report from the National Wilms Tumor Study Group.

Authors:  M H Porteus; P Narkool; D Neuberg; K Guthrie; N Breslow; D M Green; L Diller
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

Review 8.  Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor.

Authors:  J B Beckwith; N B Kiviat; J F Bonadio
Journal:  Pediatr Pathol       Date:  1990

9.  Renal abnormalities in beckwith-wiedemann syndrome are associated with 11p15.5 uniparental disomy.

Authors:  Michael Goldman; Adam Smith; Cheryl Shuman; Oana Caluseriu; Chihong Wei; Leslie Steele; Peter Ray; Paul Sadowski; Jeremy Squire; Rosanna Weksberg; Norman D Rosenblum
Journal:  J Am Soc Nephrol       Date:  2002-08       Impact factor: 10.121

10.  Methylation analysis and diagnostics of Beckwith-Wiedemann syndrome in 1,000 subjects.

Authors:  Abdulla Ibrahim; Gail Kirby; Carol Hardy; Renuka P Dias; Louise Tee; Derek Lim; Jonathan Berg; Fiona MacDonald; Peter Nightingale; Eamonn R Maher
Journal:  Clin Epigenetics       Date:  2014-06-04       Impact factor: 6.551
View more
  2 in total

1.  Characteristics Associated with Tumor Development in Individuals Diagnosed with Beckwith-Wiedemann Spectrum: Novel Tumor-(epi)Genotype-Phenotype Associations in the BWSp Population.

Authors:  Kelly A Duffy; Kelly D Getz; Evan R Hathaway; Mallory E Byrne; Suzanne P MacFarland; Jennifer M Kalish
Journal:  Genes (Basel)       Date:  2021-11-21       Impact factor: 4.096

Review 2.  Overgrowth Syndromes-Evaluation, Diagnosis, and Management.

Authors:  Joshua Manor; Seema R Lalani
Journal:  Front Pediatr       Date:  2020-10-30       Impact factor: 3.418
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.